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Background: The potentially detrimental role of progesterone during the follicular phase has been a matter of
controversy for several years; however, few studies have analyzed the effects of combined raised estradiol and
progesterone levels on pregnancy outcomes. The aim of the present study was to determine the influence of
high progesterone levels on clinical outcomes in the context of high ovarian response.
Methods: We performed a retrospective cohort study that included 2850 women classified as high responders.
The women were subdivided into six groups depending on their progesterone concentration on the day of human
chorionic gonadotropin (hCG) administration: <0.5 ng/ml (<p10), 0.50-0.70 ng/ml (p10-p25), 0.71-1.00 ng/ml (p25-p50),
1.01-1.40 ng/ml (p50-p75), 1.41-1.80 ng/ml (p75-p90) and >1.81 ng/ml (>p90). Ovarian response was classified as high
when > =20 oocytes were retrieved or when estradiol was > =3000 pg/ml. Clinical outcomes of each subgroup were
analyzed. We also examined data from frozen-thawed embryo transfers. Results were analyzed with Student’s t- test
to compare continuous variables and chi-squared test to compare proportions. A p-value of < =0.05 was considered
statistically significant.
Results: The progesterone concentration increased with ovarian response, and elevated progesterone did not show a
significant clinical impact on implantation rate and pregnancy rates. These data provide evidence that progesterone
levels higher than 1.8 ng/ml do not have detrimental effect on oocyte quality or endometrial receptivity.
Conclusions: These data allow us to conclude that high progesterone levels correlate significantly with high estradiol
levels and that in high responder women; progesterone levels do not show a significant clinical impact on results.
Keywords: Ovarian response, High responders, High progesterone, Clinical outcomesBackground
Control over estradiol secretion is explained by the two
cell- two gonadotropins theory, while control of proges-
terone synthesis is less well understood. Progesterone
plays a key role during the second phase of the menstrual
cycle and is particularly important for implantation and
progression of pregnancy; however, in the context of
stimulated cycles, the potentially detrimental role of
this hormone during the follicular phase has been the
focus of interest and a matter of controversy for several
years. Increased progesterone levels during the early* Correspondence: antonio.requena@ivi.es
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stimulation have been suggested to be associated with
a decreased probability of ongoing pregnancy [1-3];
however, many other studies have found no association
between these two parameters [4,5]. The pathogenesis
of raised peripheral concentrations of progesterone in the
late follicular phase is likely to influence the secretory
changes of the endometrium, leading to impaired endo-
metrial receptivity [6]. On the other hand, patients who
respond adequately to controlled ovarian stimulation
are more likely to produce better oocytes. Therefore,
the consequences of elevated progesterone levels on
clinical outcomes in patients with good response are
likely to result from a balance between two antagonistic
factors: the probability of getting more oocytes associatedal Ltd. This is an Open Access article distributed under the terms of the Creative
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of the endometrium resulting from the premature endo-
metrial exposure to progesterone [7].
Although increased progesterone levels have historically
been associated with LH in the context of premature
LH surges, some studies have indicated that the elevated
progesterone is due to FSH exposure during the follicular
phase [8,9]. Changes in paracrine regulation might explain
the increase in progesterone production observed in the
late follicular phase [10]; this is a pathological mechanism
that is probably associated with the high response of the
ovary during stimulation, which results in an excessive
number of follicles and proliferating granulose cells. It was
demonstrated recently that patients with high estradiol
concentrations have significantly higher progesterone
concentrations [11,12]; thus, this association suggests
that at least one of the mechanisms that play a role in
increased progesterone levels is linked to a high ovarian
response during controlled ovarian stimulation. This idea
has been recently confirmed by Griesinger et al. [13]
which show that the incidence of progesterone elevation
on the day of hCG increased with the ovarian response
from 4.5% in low responders to 19.0% in high responders.
Changes in hormone concentrations convey significant
biological messages; understanding and proving this
theory could give rise to better approaches to treatment
and risk assessment. Most studies of the association
between steroid hormones and clinical outcomes were
limited to investigating elevated levels of progesterone
or estradiol individually, rather than in combination.
Few studies have analyzed the effects of combined raised
estradiol and progesterone levels on pregnancy outcomes.
Therefore, the aim of the present study was to determine
the influence of high progesterone levels on clinical
outcomes in the context of high ovarian response.
Methods
Study population and design
This was a non-interventional, large-sample, retrospective,
multicenter cohort study of patients who underwent rou-
tine clinical examinations and procedures. A total of 2850
infertile women who were classified as high responders
and were undergoing assisted reproduction techniques
from January 2009 to December 2011 were included in
this retrospective study. These women received treatment
at one of 11 private clinics belonging to the IVI Group
in Spain. To reflect the broad range of patients typically
encountered in clinical practice, no inclusion/exclusion
criteria were applied regarding baseline characteristics.
High response was defined as women who had ≥20 oocytes
retrieved or whose estradiol levels were ≥3000 pg/ml.
All patients signed written informed consent forms.
All procedures and protocols were approved by an Insti-
tutional Review Board (reference MAD-AR-09-2013-01).It complied with the Spanish law governing assisted
reproduction technologies (14/2006).
Patients underwent controlled ovarian stimulation
with a short GnRH antagonist protocol triggered with
human chorionic gonadotropin (hCG) for pituitary down-
regulation. Ovarian stimulation was performed by one of
four possible methods: recombinant follicle stimulating
hormone (rFSH) alone (Gonal-F, Merck-Serono, Spain; or
Puregon, MSD, Spain); rFSH combined with recombinant
luteinizing hormone (rLH) (Luveris, Merck-Serono, Spain);
highly purified human menopausal gonadotropin (HP-
hMG) alone (Menopur, Ferring Pharmaceutical, Spain);
or rFSH combined with HP-hMG. Because this was a
retrospective study, no specific criteria were defined for
the selection of gonadotropins; choices were made on a
case-by-case basis according to patient characteristics and
clinician preferences. The initial dose of gonadotropin
was individualized for each patient according to age,
basal FSH levels, antral follicle count, body mass index
(BMI), and previous response to ovarian stimulation.
Dose adjustments were performed according to ovarian
response, which was monitored by vaginal scans and
estradiol determinations.
After oocyte retrieval, in vitro fertilization (IVF) or
intracytoplasmic sperm injection (ICSI) was performed.
The quality of all available embryos was evaluated, and up
to two embryos were transferred on day 3 of development.
Evaluated parameters on developmental day 3 included
cell number, symmetry, granularity, type and percentage
of fragmentation, presence of multinucleate blastomeres,
and degree of compaction as previously described [14].
A top-quality embryo was described as 4–5 cells on day
2, > = 7 cells on day 3, equally sized blastomeres and < =20%
fragmentation on day 3, and no multinucleate cells.
The β-hCG concentration was determined 13 days after
embryo transfer, and the clinical pregnancy and implant-
ation rate was confirmed when a gestational sac with fetal
heart beat was visible by ultrasound examination after
7 weeks of pregnancy.
The primary objective was to determine the relationship
between serum progesterone levels on the day of hCG
administration and the implantation and pregnancy rates
in high responder patients. As a secondary objective, we
also tried to establish, when appropriate, a serum proges-
terone threshold in this specific set of patients that
would define circulating progesterone levels that were
detrimental to cycle outcomes.
Hormonal measurements
Blood samples for the analysis of circulating estradiol and
progesterone were assessed on the day of hCG administra-
tion. Serum samples were analyzed by chemiluminescence
with the Architect analyzer (Abbot Diagnostics, Spain). The
analytical sensitivity of the estradiol assay was ≤10 pg/ml,
Table 1 Clinical characteristics of the study population
Parameters Values
Age (years) 34.8 (19–42)
BMI (kg/m2) 23.0 (19.2-31.4)
Estradiol (pg/ml) 3578.8 ± 1232
Progesterone (ng/ml) 1.3 ± 0.6
N of oocytes retrieved 19.6 (0–32)
N transferred embryos 1.75 (0–3)
N frozen embryos 5.6 (0–12)
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sensitivity of the progesterone assay was ≤0.1 ng/ml,
with a coefficient of variation of ≤7%.
Statistical analysis
To describe the distribution of the probabilities of implant-
ation and pregnancy rates, progesterone concentrations
were converted from continuous variables into categorical
variables by dividing them into groups based on their
percentiles. By employing this procedure, we avoided
bias by assuming that any relationship between serum
progesterone level and clinical outcome may be linear.
Next, patients were separated into percentiles (p10, p25,
p50, p75 and p90) and then subdivided into six distinct
groups according to their serum progesterone levels on the
day of hCG administration: <0.5 ng/ml (<p10, n = 228),
0.50-0.70 ng/ml (p10-p25, n = 409), 0.71-1.00 ng/ml
(p25-p50, n = 738), 1.01-1.40 ng/ml (p50-p75, n = 752),
1.41-1.80 ng/ml (p75-p90, n = 381) and >1.81 ng/ml
(>p90, n = 342).
The odds ratio (OR) of all of the variables generated on
implantation and pregnancy was expressed in terms of 95%
confidence interval (95% CI); the effect of progesterone
was quantified by conducting a logistic regression analysis.
The receiver operating characteristic (ROC) curve was
employed to test the predictive value of the variable proges-
terone levels included in the model with respect to implant-
ation in high ovarian response patients. ROC curve analysis
provides values for the area under the curve (AUC) that are
between 0.5 and 1.0 and can be interpreted as a measure-
ment of the global classification ability of the model.
Finally, values are expressed as mean ± standard devi-
ation (SD). One-way analysis of variance (ANOVA) with
Bonferroni post-hoc tests for continuous variables and
the chi-squared test for categorical data were used for
data analysis. Statistical analysis was performed with
the Statistical Package for Social Sciences version 19.0




A total of 2850 women defined as high responders and
undergoing GnRH antagonist cycles were included in this
study. We performed IVF or ICSI. Clinical characteristics
of the study population are presented in Table 1. Fresh
embryo transfer was performed in 1990 cycles (69.8%),
while 860 patients (30.2%) froze all of their embryos and
underwent a later frozen-thawed embryo transfer (FET).
High progesterone levels in high ovarian response
Estradiol concentrations were significantly higher as long
as the progesterone concentration increased, (p < 0.001,
Figure 1).We observed no significant differences (p = 0.456) in
the mean progesterone concentration with respect to
the type of gonadotropin that was used for ovarian
stimulation: rFSH alone (n = 728, progesterone 1.06 ng/ml),
rFSH + rLH (n = 377, progesterone 1.01 ng/ml), HP-hMG
alone (n = 370; progesterone 1.10 ng/ml); and rFSH+HP-
hMG (n = 1375; progesterone 1.30 ng/ml).
In fresh cycles, we observed a marginal significant differ-
ence (p = 0.045) in implantation rates between patients
within the progesterone interval 0.51-0.70 ng/ml (p10-
p25) and patients with progesterone levels ≥1.80 ng/ml
(>p90) (Figure 2); the OR associated with the effect of
progesterone on the implantation rate was −0.056 (95%
CI 0.031 to −0.004). These data suggest that a serum
progesterone concentration of >1.8 ng/ml may represent
the threshold level above which we can begin to observe
some kind of effect on the implantation rate; however, the
AUC was ≤ 0.5 (AUC= 0.486), showing that the analysis
was not informative.
Regarding pregnancy rates in fresh cycles, we also ob-
served minor significant differences (p = 0.044, Figure 3)
in patients with progesterone levels >1.8 ng/ml; more-
over, when we re-analyzed the data considering only two
groups (<p90 and > p90), we observed that the pregnancy
rate decreased (p = 0.048) when progesterone levels were
>1.8 ng/ml (>p90) compared to patients with progester-
one levels below this value (57.1% vs. 50.9%, respectively).
The OR associated with this probability was 0.73 (95% CI
0.61 to 0.99). As well as we checked for the implantation
rate, the ROC curve (AUC= 0.455) failed to find any pre-
diction about the influence of high progesterone levels on
pregnancy rates within a context of high ovarian response.
Among all of the patients with high ovarian response,
860 underwent a FETcycle instead of fresh embryo transfer,
because all of their embryos were frozen. Mean serum pro-
gesterone concentration in FET cycles was 1.6 ± 0.8 ng/ml.
We did not observe any significant differences in the
implantation rate (p = 0.529) among the progesterone
subgroups: <p10, 36.7%; p10-25, 38.1%; p25-p50, 39.6%;
p50-p75, 32.9%; p75-p90, 33.1%; and > p90, 38.8%. We
obtained similar results regarding the pregnancy rate: <p10,
Figure 1 High estradiol concentrations are associated with high estradiol concentrations.
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p75-p90, 56.2%; and > p90, 58.3% (p = 0.166).
Discussion
Supraphysiological serum estradiol levels are closely
related to the ovarian stimulation that is necessary for
multiple follicle development. Based on the fact that
ovarian steroid hormones regulate cyclic changes in the
endometrium, increased estradiol levels during controlled
ovarian stimulation may compromise endometrial recep-
tivity for embryo implantation. Several authors have
suggested that high responders have significantly lowerFigure 2 Implantation rates according progesterone levels. (*, p = 0.04implantation and pregnancy rates in addition to impaired
endometrial receptivity [15], while others have failed to find
an association between high estradiol levels on the day of
hCG administration and harmful effect on pregnancy out-
comes [16,17]. Although progesterone was not analyzed in
those studies, other researchers have proposed that not
only estradiol levels, but also progesterone concentrations,
affect pregnancy outcomes [1,18]. Nevertheless, the un-
favorable effect of elevated progesterone on pregnancy
outcomes has been questioned in other reviews [4,19,20].
While a wide range of estradiol concentrations during
the late follicular phase are able to accommodate successful5).
Figure 3 Pregnancy rates according progesterone levels. (*, p = 0.044).
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regarding progesterone concentrations in the late follicular
phase. When we analyzed the data with respect to fresh
cycles, the results of the present retrospective study
showed that in women classified as high responders,
implantation rates were barely significantly different
between women with 0.5-0.7 ng/ml (p10-p25) and the
highest progesterone intervals. Our data suggest that a
serum progesterone concentration exceeding 1.8 ng/ml
may represent the value at which progesterone begins
to have a minimum effect on implantation rates in
patients with high ovarian response. However, the AUC
derived from ROC analysis exhibited an uninformative
value, which suggests that progesterone concentration
in high responders is not a determinant factor that can be
used to predict clinical outcomes. These results remained
the same with respect to pregnancy rates; in both cases,
the cut-off point beyond which high progesterone could
affect clinical data shifted to higher concentrations than
those observed in women with normal ovarian response.
These results are in agreement with previous reports
[13] that showed that the incidence of elevated progester-
one increases with ovarian response and that elevated
progesterone is not associated with a decreased chance
of pregnancy in high responders. These results have
important connotations because clinical decisions, espe-
cially those related with freezing all available embryos for
transferring them in a subsequent cycle, are a common
issue in cycles with high progesterone levels the day of
triggering. According to these data it might be possible to
offer a delayed transfer as a way to avoid the risk of OHSS
and not when we find high progesterone levels at late
follicular phase, as they seem not to affect pregnancy
rates. In summary, we showed that there was a slightbut significant association between serum progesterone
values in the late follicular phase and clinical outcomes,
although this significance may have little impact at clinical
level.
The decreasing trend between progesterone concen-
tration and clinical outcomes is in agreement with the
results previously reported by Bosch et al. [3], although
our results did not reveal such a large difference in out-
comes among various progesterone concentrations. The
minimal impact of progesterone levels in high responders
on the pregnancy rate suggests that the negative effect
predicted for elevated progesterone could be overcome by
other factors with a positive effect; it is possible that high
responders may have better and faster developing embryos
that “catch up” with the hypothetical endometrial changes
owing to a premature increase in progesterone [21].
Moreover, and in agreement with this hypothesis, it has
been reported that embryos derived from women with
progesterone levels >1.1 ng/ml cleaved significantly faster
[23], which supports the idea that these embryos circum-
vent the endometrial changes associated with progester-
one secretion.
In addition, high responders exhibited a closer relation-
ship between estradiol and progesterone levels, which is in
agreement with a theory that suggests that at least one of
the mechanisms that play a role in the premature increase
of plasma progesterone is linked to the high ovarian
response of the ovary to controlled ovarian stimulation
[11]. This hypothesis (and consequently our data) has
been confirmed through a logistic regression model, which
established that the number of follicles on the day of hCG
administration might predict serum progesterone levels
[12]. What is more, the paper from Griesinger [13] and our
own results showed that women with high progesterone
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that each individual follicle contributed to the collective
observed concentration and that high serum estradiol
levels and number of oocyte retrieved were associated
with high progesterone concentrations.
Progesterone elevation may be partially caused by a lack
of uniform stimulation, as different forms containing
LH were included. Although we did not account for LH
activity, we analyzed progesterone concentrations according
to the type of gonadotropin used during controlled ovarian
stimulation, and we did not observe significant differ-
ences among them. Moreover, the absence of significant
differences between the different types of gonadotropin
illustrates that neither FSH-like nor LH-like activity
each have an effect on follicular progesterone synthesis,
and that serum progesterone levels in high responders are
determined by the degree of ovarian response instead of
the type of gonadotropin. These data do not reconcile
with previous reports that found significant differences in
progesterone levels when compared recombinant FSH vs.
hMG [10]; these differences remained even after adjusting
the results for ovarian response. In this later paper, the
number of women considered as high ovarian responders
was too small (n = 30 in the recombinant FSH group
and n = 35 in the hMG group), then these quantities
contrast sharply with our sample size, which might
explain why we did not find significant differences in
progesterone concentrations when compared different
types of medication.
It has also been suggested that raised progesterone
concentrations are likely to influence endometrial develop-
ment, which could in turn lead to a change in the normal
synchrony between the embryo and the endometrium
when excessively disturbed [24-26]. One strategy to prevent
the hypothetical effects of progesterone elevation on uterine
receptivity might be to vitrify all embryos and then transfer
embryos during a later cycle [27]. It is worthwhile to
remember the retrospective character of this study and
the fact that data collection ended in 2011; at that time,
vitrification and the use of a GnRH agonist to induce
ovulation were not systematically implemented in daily
clinical practice, which explains the proportion of fresh
embryo transfers performed in high ovarian responders.
When we analyzed clinical outcomes in FET cycles, we did
not observe significant differences in any of the variables.
These findings confirm that progesterone elevation does
not have a negative effect at the level of embryo quality
[28,29] but it does have a slight influence on endometrial
development which could be overwhelmed by the embryo
itself in this specific context of high ovarian response. At
this point, since some clinicians have recommended that
all embryos be frozen and transferred during a later
treatment, it might seem appealing that cycles could be
managed by fresh embryo transfers in high responders.Conclusions
Our results confirmed that the risk of a pre-ovulatory
rise in progesterone levels increases with the ovarian re-
sponse. In addition, a direct comparison of clinical out-
comes among women with high ovarian response who
were classified in different progesterone concentration
intervals revealed a gradually decreasing trend when
progesterone levels were >1.8 ng/ml, although this de-
clining has not clinical significance. In conclusion, clin-
ical outcomes are not affected in high responders;
moreover, the ROC curve values failed to find any pre-
diction suggesting that the clinical consequences would
be barely significant.
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